Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift - Wikidata - awgldk - TriplyDB

Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift

Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift

http://www.wikidata.org/entity/Q33786540

about

Prevention of influenza by targeting host receptors using engineered proteins In silico study of rotavirus VP7 surface accessible conserved regions for antiviral drug/vaccine design Mapping the Pareto optimal design space for a functionally deimmunized biotherapeutic candidate Amino acid deprivation using enzymes as a targeted therapy for cancer and viral infections Removing T-cell epitopes with computational protein design.Computationally driven deletion of broadly distributed T cell epitopes in a biotherapeutic candidate.HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies.Protein deimmunization via structure-based design enables efficient epitope deletion at high mutational loads Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo.Immunogenicity to biologics: mechanisms, prediction and reduction.SCHEMA-designed variants of human Arginase I and II reveal sequence elements important to stability and catalysis.GFP reporter screens for the engineering of amino acid degrading enzymes from libraries expressed in bacteria.Effect of premedications in a murine model of asparaginase hypersensitivity Depletion of T cell epitopes in lysostaphin mitigates anti-drug antibody response and enhances antibacterial efficacy in vivo.Structure-based redesign of lysostaphin yields potent antistaphylococcal enzymes that evade immune cell surveillance.Toward reducing immunogenicity of enzyme replacement therapy: altering the specificity of human β-glucuronidase to compensate for α-iduronidase deficiency.Predictions versus high-throughput experiments in T-cell epitope discovery: competition or synergy?The utility and limitations of current Web-available algorithms to predict peptides recognized by CD4 T cells in response to pathogen infection Poor correlation between T-cell activation assays and HLA-DR binding prediction algorithms in an immunogenic fragment of Pseudomonas exotoxin A.EpiSweep: Computationally Driven Reengineering of Therapeutic Proteins to Reduce Immunogenicity While Maintaining Function.Design and analysis of immune-evading enzymes for ADEPT therapy.Computationally optimized deimmunization libraries yield highly mutated enzymes with low immunogenicity and enhanced activity.Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A.Immunogenicity of therapeutic recombinant immunotoxins.Clonostachys rosea demethiolase STR3 controls the conversion of methionine into methanethiol scFv-based "Grababody" as a general strategy to improve recruitment of immune effector cells to antibody-targeted tumors.Mutations in subunit interface and B-cell epitopes improve antileukemic activities of Escherichia coli asparaginase-II: evaluation of immunogenicity in mice.Targeting methionine auxotrophy in cancer: discovery & exploration.Drug development: longer-lived proteins.Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38.Novel in silico tools for designing peptide-based subunit vaccines and immunotherapeutics.Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions.Design and engineering of deimmunized biotherapeutics.The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease.A high throughput MHC II binding assay for quantitative analysis of peptide epitopes.Studies on Deimmunization of Antileukaemic L-Asparaginase to have Reduced Clinical Immunogenicity--An in silico Approach.Discovery of human-like L-asparaginases with potential clinical use by directed evolution.Structure-based redesign of proteins for minimal T-cell epitope content Rhizobium etli asparaginase II: an alternative for acute lymphoblastic leukemia (ALL) treatment.L-methionase: a therapeutic enzyme to treat malignancies.

P2860

Q27683378-1F389BD8-1C8D-4697-BFD9-E2AB43791BA0 Q28481569-FDF96982-7630-49B4-A402-117333DB496F Q28543006-1953642B-054B-4507-872D-90E332A4F842 Q30040775-F3D96337-0EBF-4910-BB5A-882A50299011 Q30362724-BBAC64A8-2E6F-4D74-8213-EE89D7480085 Q30363065-42BE9828-08C8-4C0A-B49E-3F1ECE6532E4 Q30371340-BF82EEAD-0006-463A-ABC4-EB7DC75C289C Q30371474-1C6C4AA1-D14F-4CD9-B574-FC9CD44435CB Q33652098-2C5E544B-AE48-49C8-A14E-56A9F24CB27D Q34296526-370BF98A-5825-4C6D-8013-0FB9491CFE9C Q34318551-5CDC9965-CB0F-4BD1-B8DF-B864375F5016 Q34592385-DCE6740B-4574-4893-87A9-628F7726E1C6 Q35156439-B8430BE0-31FD-478E-972A-BBFFCBFE018A Q35638576-D15D9045-D72D-4599-BF83-FD6DFDDE4212 Q35751036-78401BE2-C60C-4AFC-A1B1-BDC78108E2A3 Q35759492-755CF766-351A-4B44-8BAD-C72B8DF2E985 Q35813585-7DC04470-3AB7-47DB-8BA5-EF5E0945C6F1 Q35903181-C1A1EFFC-1AAE-4B6D-861A-513CB2A4EE9C Q36157120-877F2A7B-019D-4ABE-975C-4011B5F0C4FB Q36212517-1C45520F-F9E6-438C-9EB6-8ACD0843C07B Q36254472-A977654C-019F-4948-9853-787C1DA5D9F3 Q36399908-D1DEBBB6-8AE3-4957-9E91-577D7B9A4387 Q36485104-8AAFD19A-3660-46DE-985C-295A0BA8C83D Q36593468-9950A6A0-EDD9-4F4F-98F8-77CD596D2CA7 Q36606141-6BF7EA3C-DFAA-4E65-AC91-DB09DCD10E3A Q36778011-EF9B881A-CDFE-4F83-9EF9-98EEB37A77EE Q37563510-398E3293-C273-4A69-9083-3AC6893BFDFF Q37968630-F3741989-524D-413A-AED6-A5B9BF06A653 Q37981866-7F65C347-586F-47A3-B159-20201487E3D6 Q38721404-48080703-B7E7-4EF6-AE28-14D41541CB28 Q38789472-39DD8205-AFEE-4511-AF96-32EC1C460B37 Q38792334-2BE695CD-78B9-4B37-A9B5-8BC8A5D75714 Q38870681-66824778-1FE6-42DD-8F95-E08FF1ABFA61 Q39663434-81FB83A7-57EB-4174-BCA3-AA5360516912 Q39766269-E02F24F0-7A31-4E4A-B244-ECBDC39C3541 Q41295156-59AED97B-47B0-483C-ABA6-9B1314CE4BB1 Q41581505-AAE05600-8CF3-4BE0-83DD-A5B293F93383 Q41988381-EC260B24-B319-487A-95BA-0E9B2E293064 Q42770604-4DADC2E5-7058-416F-B09C-A500CD983CBC Q42877755-664DB23A-7FBC-4EE6-9593-3F8B25F3FBBF

P2860

Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift

http://www.wikidata.org/entity/Q33786540

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Therapeutic enzyme deimmunizat ...... pe removal using neutral drift

@ast

Therapeutic enzyme deimmunizat ...... pe removal using neutral drift

@en

type

label

Therapeutic enzyme deimmunizat ...... pe removal using neutral drift

@ast

Therapeutic enzyme deimmunizat ...... pe removal using neutral drift

@en

prefLabel

Therapeutic enzyme deimmunizat ...... pe removal using neutral drift

@ast

Therapeutic enzyme deimmunizat ...... pe removal using neutral drift

@en

P1433

Q33786540-E1F37316-B237-4FB4-8B57-4AFCB9E4910B

P1476

Q33786540-D9974668-2C7F-452C-84B8-61434CB182B5

P2093

Q33786540-496CECA3-6C97-4F99-A899-C01546C18266

Q33786540-84EABE65-FBE7-4063-801D-43A0EB46FEB1

Q33786540-882884EA-9A2B-4D95-A178-AA1410769CF9

Q33786540-BCFBE67B-736D-4DC8-8785-3343E6D71810

Q33786540-CEA02D17-9D9F-4FA6-A288-598313F8CE48

P2860

Q33786540-00D6F40F-0870-4EEC-9119-BE4B317944DD

Q33786540-03F0CAE6-769C-4754-BFCD-41AC2E365E6F

Q33786540-0A9CBC01-40A2-4784-97A7-55F358CB1F5B

Q33786540-14A2D007-A540-4072-ABCB-E24B38EF967A

Q33786540-1C3E852D-11BB-43A0-B1EC-2FCCB73435BD

Q33786540-2271DBA9-03CE-4321-95BF-D87F6EC9100C

Q33786540-2CF1348E-5959-4B16-BB9A-D79F92008D84

Q33786540-2EA52146-3675-41B4-89C4-250EE8123D4C

Q33786540-3198EE0B-96B3-4E65-B2F9-1D33806F2FCA

Q33786540-31C1533E-F4BF-4CA8-AE30-D0183CD4C614

P304

Q33786540-107D0DE3-F147-4DD2-A787-E7C4A74C4AB8

P31

Q33786540-929009B6-1C3A-4258-9362-9FCEB7DC4AD4

P356

Q33786540-B1803C4B-F7F4-4167-8A4A-C9D70FF2278A

P407

Q33786540-119F67BC-B16C-4959-8F8A-D0F459EE4E59

P433

Q33786540-0DEA5091-4961-4270-B2E7-7353883D4F37

P478

Q33786540-50B87E56-7202-46B2-8B77-7442BC126DE5

P50

Q33786540-ACFCAE86-F6F6-4B3A-9002-4773CACCAF39

P577

Q33786540-35987D8B-ADE3-440A-BF30-5FCDF37B6151

P5875

Q33786540-EC353D1A-83A1-4BC3-B808-5EC0B8900A3E

P698

Q33786540-DB44B28B-D3F8-4B30-A1CB-84E488818E1E

P932

Q33786540-66B7D874-D595-4803-8C83-6AF6792E2DC5

P356

PNAS.1014739108

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Therapeutic enzyme deimmunizat ...... pe removal using neutral drift

@en

P2093

Aakanksha Dixit

http://www.w3.org/2001/XMLSchema#string

Brent L Iverson

http://www.w3.org/2001/XMLSchema#string

George Georgiou

http://www.w3.org/2001/XMLSchema#string

Jason R Cantor

http://www.w3.org/2001/XMLSchema#string

Tae Hyeon Yoo

http://www.w3.org/2001/XMLSchema#string

P2860

PEG-uricase in the management of treatment-resistant gout and hyperuricemia

A perspective on enzyme catalysis.

Neutral genetic drift can alter promiscuous protein functions, potentially aiding functional evolution.

Directed evolution of ampicillin-resistant activity from a functionally unrelated DNA fragment: A laboratory model of molecular evolution

Engineering of a macromolecular scaffold to develop specific protease inhibitors.

Advances in laboratory evolution of enzymes.

A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach

Directed enzyme evolution via small and effective neutral drift libraries.

The kinetics of two-dimensional TCR and pMHC interactions determine T-cell responsiveness.

Asparagine synthetase activity of mouse leukemias.

P304

1272-1277

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1014739108

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P50

Thomas G Forsthuber

P577

2011-01-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49731777

http://www.w3.org/2001/XMLSchema#string

P698

21209329

http://www.w3.org/2001/XMLSchema#string

P932

3029727

http://www.w3.org/2001/XMLSchema#string